Skip to main content
OpenTrials
Completed

NCT Number: NCT06935565

Clinical Performance of the Asqelio™ Trifocal Diffractive Intraocular Lens

The goal of this observational study is to evaluate whether the Asqelio™ Trifocal intraocular lens (IOL) can improve refractive outcomes and optical quality in patients (aged ≥45 years) undergoing cataract surgery or clear lens exchange, including both male and female participants. The main questions it aims to answer are:

* Does the Asqelio™ Trifocal IOL provide accurate refractive correction with minimal residual refractive error? * Does the lens reduce light distortion and provide good visual acuity at multiple distances (far, intermediate, near)?

Researchers will not use a comparison group, as this is a post-marketing, single-arm observational study.

Participants will undergo bilateral implantation of the Asqelio™ Trifocal IOL during cataract or lens replacement surgery and attend a study follow-up exam approximately 270±90 days post-surgery.

Complete evaluations including:

* Manifest refraction testing * Uncorrected and corrected visual acuity at far, intermediate, and near distances * Binocular defocus curve analysis * Contrast sensitivity testing * Light distortion analysis using a Light Distortion Analyzer * Patient-reported outcomes via the Catquest-9SF and visual symptoms questionnaires.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cataract Eye Diseases Lens Diseases

Age range

50 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Clinica Baviera

Seville, 41013, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients 50 years of age or older undergoing cataract surgery by phacoemulsification and binocular IOL implant AsqelioTM Trifocal TFLIO130C
  • Independence of use of glasses after surgery.
  • IOL power between +5.0D and +34.0D
  • Transparent intraocular media except for cataracts in both eyes.
  • Potential postoperative visual acuity of 20/25 or better.

Exclusion criteria

  • Preoperative corneal astigmatism greater than 1.0D
  • Previous corneal surgery or trauma.
  • Irregular cornea (e.g. keratoconus)
  • Choroidal hemorrhage
  • Microphtalmos
  • Severe corneal dystrophy
  • Uncontrolled or medically controlled glaucoma
  • Clinically significant macular changes
  • Concomitant severe eye disease
  • Non-age-related cataract
  • Severe optic nerve atrophy
  • Diabetic retinopathy
  • Proliferative diabetic retinopathy
  • Amblyopia
  • Extremely shallow anterior camera
  • Severe chronic uveitis
  • Pregnant or nursing
  • Rubella
  • Mature/dense cataract that makes it difficult to examine the eye fundus preoperatively.
  • Previous retinal detachment
  • Concurrent participation in other research with drugs or clinical devices

Treatment and study plan

Trifocal IOL implantation

Other

Patients were implanted bilaterally with Asqelio Trifocal IOL 270±90 days before study visit

Primary outcomes

  1. Residual refraction

    Time frame: 270±90 days after surgery

    Residual refractive error determined by subjective refraction procedures and expressed in diopters of spherical and cylindrical power

  2. Light Distortion Index

    Time frame: 270±90 days from surgery

    The distortion index is calculated as the ratio of the area of points missed by the subject and the total area explored using the Light Distortion Analyzer, and is expressed as a percentage

Secondary outcomes

  1. Visual acuity

    Time frame: 270±90 days after surgery

    The VA with its best correction placed under photopic conditions was determined monocularly at a distance of 4 meters (UDVA and BCDVA), 60 cm (UIVA and BDCIVA), 40 cm (UNVA and BDCNVA), using the optotype of letters Early Treatment Diabetic Retinopathy Study (ETDRS)

  2. Binocular defocus curve

    Time frame: 270±90 days after surgery

    Binocular defocus curve was obtained by varying the stimulus vergence from -4.0 D to +2.0 D in 0.5 D steps with the best correction for distance vision

  3. Contrast sensitivity

    Time frame: 270±90 days after surgery

    The spatial profile of the stimulus was configured to diplay sinusoidal patterns in a circular window with sharp or smoothed edges. The patient's task was to describe the orientation of the stimulus, which changes at random among three options: vertical (grating at 0°), right (15°), or left (-15°), using the Topcon CC-100 instrument

  4. Patient-Reported Outcomes - CATQuest9SF

    Time frame: 270±90 days after surgery

    9-item questionnaire to determine patient activity limitations in daily life due to poor vision used due to its documented responsiveness in cataract surgery. It comprises 9 items with 4 response options, ranging from 4 for "very great difficulty/very dissatisfied" to 1 for "no difficulty/very satisfied", and a "cannot decide" additional option, which is treated as missing data. The questionnaire responses were scored using the Likert scale, from 1 for no difficulty/very satisfied, to 4 for very great difficulty/very dissatisfied.

  5. Patient-Reported Outcomes - Visual symptoms

    Time frame: 270±90 days after surgery

    A visual symptoms questionnaire explores the frequency, intensity and bothersome of 10 different and common visual symptoms. These symptoms are: Glare, Haloes, Starbursts, Foggy vision, Blurred vision, Distortion, Double vision, Fluctuation in vision, Difficulty focusing, and Difficulty judging distances or depth. A simulated image is shown to the patient to aid in the description of each of the symptoms, and they are asked to respond with 4 response options to the frequency of the symptoms, from 1 for "Never" to 4 "Very often", the intensity of the symptom, from 1 for "None" to 4 for "Severe", and the level of bothersome of the symptom, from 1 for "None" to 4 for "A lot". The scoring of these responses ranges from 0 for Never/None to 3 for Very Often/Severe/A lot

Sponsors and collaborators

Lead sponsor

AST Products, Inc.

Industry

Registry information

Important dates

Study start
2022
Primary completion
2023
Study completion
2024
First posted
Apr 20, 2025
Registry last updated
Apr 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.